X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Indian equity markets trade flat 
(Wed, 22 Aug 11:30 am) 
 
Indian equity markets continued to trade flat over the last two hours of trade. Pharma and Auto stocks witnessed maximum buying interest, while Capital Goods and Realty stocks witnessed maximum selling pressure.

The Sensex today is down by 30 points, while the NSE-Nifty today is down by 9 points. BSE Mid Cap index and the BSE Small Cap index are up by 0.22% and 0.33% respectively. The rupee is trading at 55.54 to the US dollar.

Steel stocks are trading in the red led by JSW Steel and Jindal Steel. According to a leading financial daily, Tata Steel will pay US$ 471 m to holders of its foreign currency convertible bonds (FCCBs) that are maturing on September 5. The company had issued these convertible bonds in 2007 and bondholders were supposed to give notice of conversion into shares by August 6. However, the company has stated that it did not receive any such notice by the given time and therefore, it will be paying US$ 471 m as principal along with an interest of US$ 1.92 m against the bonds for the last six months. The company, however, did not disclose the conversion price of the bonds.

Pharma stocks are trading strong led by Ranbaxy and Orchid Chemicals. According to a leading financial daily, Cipla is planning to enter into a joint venture with South Africa's Aspen Pharmacare to cater to the Australian market. Under the pact, Cipla would develop generic products, to be launched by Aspen in Australia. The move follows a recent buyout by Aspen in the Australian pharmaceutical space. The company had acquired the over-the-counter and pharmaceutical divisions of Australian drug maker Sigma Pharmaceuticals for US$ 800 m. Cipla, which has traditionally supplied low-cost generic drugs to foreign partners, may see a rise in its export revenue once the joint venture is operational. This is because the Australian pharmaceutical market is relatively small and is growing at single-digit rate and could be a lucrative market for companies manufacturing low-cost products.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "Indian equity markets trade flat". Click here!

  
 

S&P BSE SENSEX


Apr 24, 2017 12:51 PM

MARKET STATS